Cushing&rsquo;s Disease is a rare endocrine disorder caused by a pituitary tumor that leads to excessive production of adrenocorticotropic hormone (ACTH). This, in turn, stimulates the adrenal glands to produce too much cortisol, the body&rsquo;s main stress hormone.
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total diagnosed prevalent cases of Cushing&rsquo;s disease
</li>
<li dir="ltr" aria-level="1">
Gender-specific diagnosed prevalent cases of Cushing&rsquo;s disease
</li>
<li dir="ltr" aria-level="1">
Age-specific diagnosed prevalent cases of Cushing&rsquo;s disease
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/cushings-disease-epidemiology-forecast">Cushing&rsquo;s Disease Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, there were about 37,100 diagnosed prevalent cases of Cushing&rsquo;s disease in the 7MM.
</li>
<li dir="ltr" aria-level="1">
The U.S. had approximately 19,950 diagnosed cases, expected to rise by 2034.
</li>
<li dir="ltr" aria-level="1">
In the U.S., gender-specific cases included ~4,450 males and ~15,500 females.
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK reported around 12,400 cases in 2024, with ~2,650 in males and ~9,750 in females.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/cushings-disease-market">Cushing&rsquo;s Disease Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the U.S. led the Cushing&rsquo;s disease market with nearly USD 930 million in revenue.
</li>
<li dir="ltr" aria-level="1">
EU4 and the UK contributed around USD 85 million, with Germany holding the largest share among them.
</li>
<li dir="ltr" aria-level="1">
Japan&rsquo;s market size was approximately USD 45 million in 2024 and is expected to grow significantly by 2034.
</li>
<li dir="ltr" aria-level="1">
Mifepristone (KORLYM and generics) generated the highest revenue among all current therapies in the U.S. in 2024.
</li>
</ul>
<h3 dir="ltr">Cushing&rsquo;s Disease Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
New drug developments, including cortisol synthesis inhibitors and glucocorticoid receptor antagonists, are improving disease management and driving market growth.
</li>
<li dir="ltr" aria-level="1">
Growing recognition of Cushing&rsquo;s disease and better diagnostic tools are leading to earlier detection and higher treatment rates.
</li>
</ul>
<h3 dir="ltr">Cushing&rsquo;s Disease Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
As a rare condition, the small number of diagnosed cases restricts commercial potential and investment.
</li>
<li dir="ltr" aria-level="1">
Expensive therapies, such as mifepristone and newly approved drugs, can limit patient access and strain healthcare budgets.
</li>
</ul>
<h3 dir="ltr">Cushing&rsquo;s Disease Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
Relacorilant (CORT125134)
</li>
<li dir="ltr" aria-level="1">
Clofutriben (SPI-62)
</li>
<li dir="ltr" aria-level="1">
Atumelnant (CRN04894)
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr">Cushing&rsquo;s Disease Key Players</h3>
<ul>
<li dir="ltr" aria-level="1">
Xeris Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
Recordati
</li>
<li dir="ltr" aria-level="1">
Corcept Therapeutics
</li>
<li dir="ltr" aria-level="1">
Sparrow Pharmaceuticals
</li>
<li dir="ltr" aria-level="1">
H. Lundbeck
</li>
<li dir="ltr" aria-level="1">
Stero Therapeutics
</li>
<li dir="ltr" aria-level="1">
Crinetics Pharmaceuticals
</li>
</ul>
And others.

Cushing’s Disease Market Infographic

Cushing’s Disease Market

Cushing’s Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape